Study of GI-102 and GIB-7 for aging in healthy adults and cancer survivors
Part of Cancer clinical trials.
This trial tests whether a combination of two drugs, GI-102 and GIB-7, can affect markers of aging in healthy people and in people who have had cancer. It aims to see if these drugs might help slow or improve aging-related changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You should be in generally good health without a life-threatening illness or disability.
- If you have had cancer, it must have been treated with curative intent and you must have been in remission for at least 12 months (or disease-free for 2 years or more). You cannot be on active cancer treatment except maintenance therapies like hormone therapy.
- You must agree to use effective contraception if you or your partner could become pregnant.
- You cannot have severe chronic diseases like advanced heart disease, kidney failure, or uncontrolled diabetes.
- You must be able to walk without a walker or wheelchair and perform daily activities independently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding extra support from a geriatric team and a pharmacist can help older patients (70+) take their oral cancer pills safely and effectively. You may be able to join if you are starting one of the listed oral therapies for your cancer.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This study looks at how older adults with gastrointestinal cancer manage their health and well-being. It aims to understand and improve care for this group.
This study aims to improve care for younger adults (ages 18-50) with gastrointestinal (GI) tumors. Researchers will test ways to better support patients during and after treatment. If you are 18-50 and being treated for a GI tumor at Heidelberg University Hospital, you may be able to join.
This study is testing an experimental medication called GNC-077 that may help treat certain advanced cancers, especially those in the digestive system. The goal is to see if the drug is safe and how well it works in people who have already tried standard treatments.
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
Hear when a new Cancer Survivors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.